US EditionUPDATED: Klotho Neurosciences, Inc. to Expand Development Programs Beyond Neurology
NEW YORK, JUL 25 – Klotho Neurosciences aims to slow biological aging by expanding into muscle strength and bone health, targeting multiple age-related disorders linked to declining Klotho levels.
- On July 24 and 25, 2025, Klotho Neurosciences, Inc. announced it is evaluating acquiring complementary technologies to support brain, organ health, and longevity.
- This expansion follows the company's focus on developing gene and cell therapies using a patented protein from the anti-aging Klotho gene to treat neurodegenerative diseases.
- Klotho's current programs include proprietary DNA and RNA therapies targeting ALS, Alzheimer's, and Parkinson's, along with genomics diagnostics and novel delivery systems.
- CEO Dr. Joseph Sinkule announced that the company has initiated production and clinical trials for KLTO-101 and KLTO-202, while also investigating additional therapies aimed at promoting healthy aging and increasing lifespan.
- The company is bringing together experts to pinpoint longevity biomarkers—including alpha-Klotho, beta-Klotho, FOXO3, and anti-myostatin—with the goal of delaying the onset of age-associated diseases and extending healthy lifespan.
Insights by Ground AI
Does this summary seem wrong?
69 Articles
69 Articles
Coverage Details
Total News Sources69
Leaning Left6Leaning Right6Center21Last UpdatedBias Distribution64% Center
Bias Distribution
- 64% of the sources are Center
64% Center
L 18%
C 64%
R 18%
Factuality
To view factuality data please Upgrade to Premium
